This webinar will discuss a set of in vitro assays that tackle the challenges of in vitro hepatotoxicity assessment.

The U.S. Food and Drug Administration approved Marlborough, Massachusetts-based Sunovion Pharmaceuticals’ Kynmobi (apomorphine HCl) sublingual film for Parkinson’s disease.

A research study in mice by investigators at the University of Rochester Medical Center suggests it would be possible to repair the brain cell damage caused by multiple sclerosis (MS).

A brief roundup of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Geneius Biotechnology is developing T cells as a quasi-personalized, off-the-shelf, therapy and preventive measure against COVID-19.

As Tocagen heads into a reverse merger with privately held Forte Biosciences, San Diego-based Denovo Biopharma swooped in to snap up that company’s retroviral replicating vector platform (RRV), including an asset that stumbled in a Phase III study that Denovo believes still has some life.

Plurisitem Therapeutics’ PLX (Placental eXpanded) cells are showing promise as a therapy for patients with severe cases of COVID-19.

Gilead Sciences, Kite, and oNKo-innate announced that the companies entered into a three-year cancer immunotherapy research collaboration to support the discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.

Ligandal is reportedly the only company developing a prospective “antidote” and vaccine in a single platform for COVID-19, with an approach that could actually help eliminate the virus from an already-infected host, while also bolstering the immune response.

Pinpoint Therapeutics believes that the company’s approach to treat therapy-resistant cancers also may be effective against COVID-19.